Amicus Therapeutics (FOLD) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
August 4, 2022 7:00 AM EDT1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7%
On-Track to Deliver Full-Year Double-Digit Revenue Growth of 15-20%Â at Constant Exchange Rates
Advancing U.S. and EU Regulatory Reviews and Launch Preparations for AT-GAA in Pompe Disease
3 Newly Issued U.S. Composition of Matter Patents for... More
